68 related articles for article (PubMed ID: 23614566)
21. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.
Islam F; Marshe VS; Magarbeh L; Frey BN; Milev RV; Soares CN; Parikh SV; Placenza F; Strother SC; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
Transl Psychiatry; 2022 Sep; 12(1):366. PubMed ID: 36068210
[TBL] [Abstract][Full Text] [Related]
22. Assessing cytochrome P450 function using genetically engineered mouse models.
Hannon SL; Ding X
Adv Pharmacol; 2022; 95():253-284. PubMed ID: 35953157
[TBL] [Abstract][Full Text] [Related]
23. Drug Metabolism: A Half-Century Plus of Progress, Continued Needs, and New Opportunities.
Guengerich FP
Drug Metab Dispos; 2023 Jan; 51(1):99-104. PubMed ID: 35868640
[TBL] [Abstract][Full Text] [Related]
24.
Ahmad HI; Afzal G; Jamal A; Kiran S; Khan MA; Mehmood K; Kamran Z; Ahmed I; Ahmad S; Ahmad A; Hussain J; Almas S
Biomed Res Int; 2021; 2021():5574789. PubMed ID: 34046497
[TBL] [Abstract][Full Text] [Related]
25. Alterations of Cytochrome P450s and UDP-Glucuronosyltransferases in Brain Under Diseases and Their Clinical Significances.
Sheng Y; Yang H; Wu T; Zhu L; Liu L; Liu X
Front Pharmacol; 2021; 12():650027. PubMed ID: 33967789
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 Metabolism of Polyunsaturated Fatty Acids and Neurodegeneration.
Sarparast M; Dattmore D; Alan J; Lee KSS
Nutrients; 2020 Nov; 12(11):. PubMed ID: 33207662
[TBL] [Abstract][Full Text] [Related]
27. Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice.
Stocco MR; Tolledo C; Wadji FB; Gonzalez FJ; Miksys S; Tyndale RF
Mol Neurobiol; 2020 Nov; 57(11):4608-4621. PubMed ID: 32761352
[TBL] [Abstract][Full Text] [Related]
28. Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice.
Tolledo C; Stocco MR; Miksys S; Gonzalez FJ; Tyndale RF
Mol Neurobiol; 2020 Jun; 57(6):2509-2520. PubMed ID: 32189192
[TBL] [Abstract][Full Text] [Related]
29. Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.
Tolledo EC; Miksys S; Gonzalez FJ; Tyndale RF
Br J Pharmacol; 2020 Feb; 177(3):701-712. PubMed ID: 31648367
[TBL] [Abstract][Full Text] [Related]
30. β-Naphtoflavone and Ethanol Induce Cytochrome P450 and Protect towards MPP⁺ Toxicity in Human Neuroblastoma SH-SY5Y Cells.
Fernandez-Abascal J; Ripullone M; Valeri A; Leone C; Valoti M
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373287
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of sauna detoxification for the protracted withdrawal symptoms of substance abuse.
Lennox RD; Cecchini-Sternquist M
J Int Med Res; 2018 Nov; 46(11):4480-4499. PubMed ID: 30209965
[TBL] [Abstract][Full Text] [Related]
32. Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations.
Bedada W; de Andrés F; Engidawork E; Hussein J; LLerena A; Aklillu E
Sci Rep; 2018 Aug; 8(1):12726. PubMed ID: 30143732
[TBL] [Abstract][Full Text] [Related]
33. P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity.
Bissig KD; Han W; Barzi M; Kovalchuk N; Ding L; Fan X; Pankowicz FP; Zhang QY; Ding X
Drug Metab Dispos; 2018 Nov; 46(11):1734-1744. PubMed ID: 30093418
[TBL] [Abstract][Full Text] [Related]
34. Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice.
Jiang XL; Shen HW; Mager DE; Schmidt S; Yu AM
Acta Pharm Sin B; 2016 Sep; 6(5):492-503. PubMed ID: 27709018
[TBL] [Abstract][Full Text] [Related]
35. In situ hybridization study of CYP2D mRNA in the common marmoset brain.
Shimamoto Y; Niimi K; Kitamura H; Tsubakishita S; Takahashi E
Exp Anim; 2016 Nov; 65(4):465-471. PubMed ID: 27356856
[TBL] [Abstract][Full Text] [Related]
36. Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.
Jiang XL; Shen HW; Yu AM
Pharmacol Rep; 2016 Jun; 68(3):608-15. PubMed ID: 26977821
[TBL] [Abstract][Full Text] [Related]
37. Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.
Tracy TS; Chaudhry AS; Prasad B; Thummel KE; Schuetz EG; Zhong XB; Tien YC; Jeong H; Pan X; Shireman LM; Tay-Sontheimer J; Lin YS
Drug Metab Dispos; 2016 Mar; 44(3):343-51. PubMed ID: 26681736
[TBL] [Abstract][Full Text] [Related]
38. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.
Tay-Sontheimer J; Shireman LM; Beyer RP; Senn T; Witten D; Pearce RE; Gaedigk A; Gana Fomban CL; Lutz JD; Isoherranen N; Thummel KE; Fiehn O; Leeder JS; Lin YS
Pharmacogenomics; 2014 Dec; 15(16):1947-62. PubMed ID: 25521354
[TBL] [Abstract][Full Text] [Related]
39. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
Jiang XL; Shen HW; Yu AM
Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
[TBL] [Abstract][Full Text] [Related]
40. Addressing phenoconversion: the Achilles' heel of personalized medicine.
Shah RR; Smith RL
Br J Clin Pharmacol; 2015 Feb; 79(2):222-40. PubMed ID: 24913012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
